Electroporation therapy: a new approach for the treatment of head and neck cancer
Electroporation can deliver exogenous molecules like drugs and genes into cells by pulsed electric fields through a temporary increase in cell membrane permeability. This effect is being used for the treatment of cancer by intratumoral injection of low dosage of an otherwise marginally effective che...
Saved in:
Published in | IEEE transactions on biomedical engineering Vol. 46; no. 6; pp. 752 - 759 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
New York, NY
IEEE
01.06.1999
Institute of Electrical and Electronics Engineers |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Electroporation can deliver exogenous molecules like drugs and genes into cells by pulsed electric fields through a temporary increase in cell membrane permeability. This effect is being used for the treatment of cancer by intratumoral injection of low dosage of an otherwise marginally effective chemotherapeutic drug, bleomycin. Application of a pulsed electric field results in substantially higher uptake of the drug and enhanced killing of the cancer cells than is possible by conventional methods. The MedPulser(R), a new treatment system for local electroporation therapy (EPT) of head and neck tumors was developed and is described in this paper. EPT with bleomycin has been found to be very effective in killing cancer cells in vitro, in mouse tumor xenografts in vivo, and in tumors in humans. Ten head and neck cancer patients with recurring or unresponsive tumors were enrolled in a Phase I/II clinical trial. Treatment of the entire turner mass in each of eight patients resulted in five complete responses confirmed by biopsy and MRI, and three partial responses (/spl ges/50% shrinkage). Two additional patients who received partial treatment of their tumor mass had local response where treated, but no overall lesion remission. Duration of the complete responses ranges from 2-10 months to date. All patients tolerated the treatment well with no significant local or systemic adverse effects. |
---|---|
AbstractList | Electroporation can deliver exogenous molecules like drugs and genes into cells by pulsed electric fields through a temporary increase in cell membrane permeability. This effect is being used for the treatment of cancer by intratumoral injection of low dosage of an otherwise marginally effective chemotherapeutic drug, bleomycin. Application of a pulsed electric field results in substantially higher uptake of the drug and enhanced killing of the cancer cells than is possible by conventional methods. The MedPulser, a new treatment system for local electroporation therapy (EPT) of head and neck tumors was developed and is described in this paper. EPT with bleomycin has been found to be very effective in killing cancer cells in vitro, in mouse tumor xenografts in vivo, and in tumors in humans. Ten head and neck cancer patients with recurring or unresponsive tumors were enrolled in a Phase I/II clinical trial. Treatment of the entire tumor mass in each of eight patients resulted in five complete responses confirmed by biopsy and MRI, and three partial responses (> or = 50% shrinkage). Two additional patients who received partial treatment of their tumor mass had local response where treated, but no overall lesion remission. Duration of the complete responses ranges from 2-10 months to date. All patients tolerated the treatment well with no significant local or systemic adverse effects. Electroporation can deliver exogenous molecules like drugs and genes into cells by pulsed electric fields through a temporary increase in cell membrane permeability. This effect is being used for the treatment of cancer by intratumoral injection of low dosage of an otherwise marginally effective chemotherapeutic drug, bleomycin. Application of a pulsed electric field results in substantially higher uptake of the drug and enhanced killing of the cancer cells than is possible by conventional methods. The MedPulser, a new treatment system for local electroporation therapy (EPT) of head and neck tumors was developed and is described in this paper. EPT with bleomycin has been found to be very effective in killing cancer cells in vitro, in mouse tumor xenografts in vivo, and in tumors in humans. Ten head and neck cancer patients with recurring or unresponsive tumors were enrolled in a Phase I/II clinical trial. Treatment of the entire tumor mass in each of eight patients resulted in five complete responses confirmed by biopsy and MRI, and three partial responses ( greater than or equal to 50% shrinkage). Two additional patients who received partial treatment of their tumor mass had local response where treated, but no overall lesion remission. Duration of the complete responses ranges from 2-10 months to date. All patients tolerated the treatment well with no significant local or systemic adverse effects. Electroporation can deliver exogenous molecules like drugs and genes into cells by pulsed electric fields through a temporary increase in cell membrane permeability. This effect is being used for the treatment of cancer by intratumoral injection of low dosage of an otherwise marginally effective chemotherapeutic drug, bleomycin. Application of a pulsed electric field results in substantially higher uptake of the drug and enhanced killing of the cancer cells than is possible by conventional methods. The MedPulser(R), a new treatment system for local electroporation therapy (EPT) of head and neck tumors was developed and is described in this paper. EPT with bleomycin has been found to be very effective in killing cancer cells in vitro, in mouse tumor xenografts in vivo, and in tumors in humans. Ten head and neck cancer patients with recurring or unresponsive tumors were enrolled in a Phase I/II clinical trial. Treatment of the entire turner mass in each of eight patients resulted in five complete responses confirmed by biopsy and MRI, and three partial responses (/spl ges/50% shrinkage). Two additional patients who received partial treatment of their tumor mass had local response where treated, but no overall lesion remission. Duration of the complete responses ranges from 2-10 months to date. All patients tolerated the treatment well with no significant local or systemic adverse effects. Electroporation can deliver exogenous molecules like drugs and genes into cells by pulsed electric fields through a temporary increase in cell membrane permeability. This effect is being used for the treatment of cancer by intratumoral injection of low dosage of an otherwise marginally effective chemotherapeutic drug, bleomycin. Application of a pulsed electric field results in substantially higher uptake of the drug and enhanced killing of the cancer cells than is possible by conventional methods. The MedPulser(R), a new treatment system for local electroporation therapy (EPT) of head and neck tumors was developed and is described in this paper. EPT with bleomycin has been found to be very effective in killing cancer cells in vitro, in mouse tumor xenografts in vivo, and in tumors in humans. Ten head and neck cancer patients with recurring or unresponsive tumors were enrolled in a Phase I/II clinical trial. Treatment of the entire turner mass in each of eight patients resulted in five complete responses confirmed by biopsy and MRI, and three partial responses ( 50% shrinkage). Two additional patients who received partial treatment of their tumor mass had local response where treated, but no overall lesion remission. Duration of the complete responses ranges from 2-10 months to date. All patients tolerated the treatment well with no significant local or systemic adverse effects |
Author | Hofmann, G.A. Dev, S.B. Nanda, G.S. Dimmer, S. |
Author_xml | – sequence: 1 givenname: G.A. surname: Hofmann fullname: Hofmann, G.A. organization: Genetronics Inc., San Diego, CA, USA – sequence: 2 givenname: S.B. surname: Dev fullname: Dev, S.B. – sequence: 3 givenname: S. surname: Dimmer fullname: Dimmer, S. – sequence: 4 givenname: G.S. surname: Nanda fullname: Nanda, G.S. |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1798529$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/10356882$$D View this record in MEDLINE/PubMed |
BookMark | eNqF0U1rFTEUBuAgLfa2unDrQrKQiovRfH-4K6XVQkEEXQ9nkjPc0bmTMZmL9N83l7moK129hPNwEvKek5MpTUjIC87ecc78-5rWKK_FE7LhWrtGaMlPyIYx7hovvDoj56V8r0fllHlKzjiT2jgnNuTLzYhhyWlOGZYhTXTZYob54QMFOuEvCvOcE4Qt7VM-zOiSEZYdTgtNPd0iRApTrDT8oAGmgPkZOe1hLPj8mBfk2-3N1-tPzf3nj3fXV_dNUEIuDTgXI-Oxi6rzvTTaMmZi1KYXKrDII2jLrfJd76KQ1loMlYHphGXchCgvyJt1b33gzz2Wpd0NJeA4woRpX1rPmVFOK1Xl5T-lcFIJbeX_IZdeWiYqfLvCkFMpGft2zsMO8kPLWXuo5JBrJdW-Oi7ddzuMf8m1gwpeHwGUAGOf6zcO5Y-z3mnhK3u5sgERf0-PlzwCytmbnw |
CODEN | IEBEAX |
CitedBy_id | crossref_primary_10_1586_14737140_6_5_671 crossref_primary_10_1088_0031_9155_55_4_021 crossref_primary_10_1103_PhysRevE_65_041920 crossref_primary_10_1109_TDEI_2009_5293942 crossref_primary_10_1002_bem_10054 crossref_primary_10_1039_C5SM02029H crossref_primary_10_1080_0284186X_2016_1207803 crossref_primary_10_1109_TDEI_2009_5211853 crossref_primary_10_1103_PhysRevE_65_021913 crossref_primary_10_1016_j_jbiotec_2004_01_015 crossref_primary_10_1371_journal_pone_0080167 crossref_primary_10_3892_ijo_2013_1774 crossref_primary_10_1186_1756_9966_28_53 crossref_primary_10_1109_TPS_2010_2048045 crossref_primary_10_1038_srep10980 crossref_primary_10_1109_TBME_2003_818466 crossref_primary_10_1109_TBME_2003_818467 crossref_primary_10_1002_pros_21303 crossref_primary_10_1007_s00192_018_3625_3 crossref_primary_10_1155_2017_3624613 crossref_primary_10_3390_cancers13091993 crossref_primary_10_1103_PhysRevE_62_1025 crossref_primary_10_1111_j_1525_1594_2005_29085_x crossref_primary_10_1016_j_snb_2013_12_107 crossref_primary_10_1038_sj_gt_3301799 crossref_primary_10_1227_01_NEU_0000350864_78326_14 crossref_primary_10_1021_ac900055r crossref_primary_10_3892_mmr_2013_1421 crossref_primary_10_1016_j_ymthe_2003_08_002 crossref_primary_10_1109_TPS_2002_804177 crossref_primary_10_1109_TBME_2005_845212 crossref_primary_10_1080_15368378_2019_1706553 crossref_primary_10_3390_cancers13061418 crossref_primary_10_1089_10849780152752092 crossref_primary_10_1088_0022_3727_49_36_364003 crossref_primary_10_1080_00016480310001114 crossref_primary_10_3390_ijms17081130 crossref_primary_10_1016_j_colsurfb_2007_02_008 crossref_primary_10_1088_0031_9155_51_12_012 crossref_primary_10_1155_SRCM_2006_85234 crossref_primary_10_1016_j_aorl_2006_08_004 crossref_primary_10_1038_s41598_019_39433_6 crossref_primary_10_1063_1_4901248 crossref_primary_10_1109_27_842905 crossref_primary_10_1109_TDEI_2003_1237327 crossref_primary_10_1177_153303460200100110 crossref_primary_10_1016_j_vaccine_2008_03_058 crossref_primary_10_1109_TPS_2004_832621 crossref_primary_10_1088_1742_6596_1704_1_012004 crossref_primary_10_1016_j_abb_2010_03_008 crossref_primary_10_1109_MEI_2013_6410537 crossref_primary_10_1016_j_snb_2012_02_065 crossref_primary_10_1016_j_sna_2005_05_017 crossref_primary_10_1016_j_bbamem_2014_03_010 crossref_primary_10_1088_0031_9155_59_20_6031 crossref_primary_10_1109_TDEI_2009_5293934 crossref_primary_10_4028_www_scientific_net_AMR_586_421 crossref_primary_10_1016_j_bioelechem_2004_07_004 crossref_primary_10_1209_0295_5075_134_68003 crossref_primary_10_1109_TBME_2014_2367543 crossref_primary_10_1109_TPS_2008_917307 crossref_primary_10_1211_0022357021778268 crossref_primary_10_1109_TPS_2014_2308871 crossref_primary_10_3892_mmr_2012_780 crossref_primary_10_3892_mmr_2014_2953 crossref_primary_10_1109_TBME_2006_889196 crossref_primary_10_1109_TPS_2004_830971 crossref_primary_10_1016_j_ejso_2005_04_007 crossref_primary_10_1007_s11517_009_0508_2 crossref_primary_10_22270_jddt_v11i3_4827 crossref_primary_10_4103_jcrt_jcrt_414_21 crossref_primary_10_1103_PhysRevE_64_011913 crossref_primary_10_1016_S0264_410X_00_00087_6 crossref_primary_10_1007_s10544_008_9220_5 crossref_primary_10_3390_electronics8121477 |
Cites_doi | 10.1016/0005-2736(77)90252-8 10.1002/ijc.2910540413 10.3322/canjclin.46.1.5 10.1016/S0304-4165(96)00147-X 10.1109/MEMB.1986.5006335 10.3109/10717549709052016 10.1006/bbrc.1993.1911 10.1007/978-1-4899-2528-2 10.1016/0302-4598(95)01827-2 10.1016/0006-2952(88)90344-9 10.1016/0304-4165(67)90052-9 10.1016/0005-2736(85)90501-2 10.1177/000348949810700908 10.1128/MCB.14.3.1815 10.1016/0005-2736(94)90045-0 10.1109/MEMB.1996.936254 10.1016/0277-5379(91)90065-L 10.1016/0302-4598(94)80026-X 10.1007/BF01867861 10.1016/0305-7372(94)90013-2 10.1016/0006-291X(86)91084-3 10.1002/(SICI)1097-0142(19960301)77:5<964::AID-CNCR24>3.0.CO;2-0 |
ContentType | Journal Article |
Copyright | 1999 INIST-CNRS |
Copyright_xml | – notice: 1999 INIST-CNRS |
DBID | RIA RIE IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7U5 8FD L7M 7QO FR3 P64 |
DOI | 10.1109/10.764952 |
DatabaseName | IEEE All-Society Periodicals Package (ASPP) 1998–Present IEEE Electronic Library (IEL) Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Solid State and Superconductivity Abstracts Technology Research Database Advanced Technologies Database with Aerospace Biotechnology Research Abstracts Engineering Research Database Biotechnology and BioEngineering Abstracts |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Technology Research Database Advanced Technologies Database with Aerospace Solid State and Superconductivity Abstracts Engineering Research Database Biotechnology Research Abstracts Biotechnology and BioEngineering Abstracts |
DatabaseTitleList | MEDLINE Engineering Research Database Technology Research Database |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: RIE name: IEEE Electronic Library (IEL) url: https://proxy.k.utb.cz/login?url=https://ieeexplore.ieee.org/ sourceTypes: Publisher |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Engineering |
EISSN | 1558-2531 |
EndPage | 759 |
ExternalDocumentID | 401812 10_1109_10_764952 10356882 1798529 764952 |
Genre | orig-research Clinical Trial, Phase II Clinical Trial, Phase I Clinical Trial Journal Article |
GroupedDBID | --- -~X .55 .DC .GJ 0R~ 29I 4.4 53G 5GY 5RE 5VS 6IF 6IK 6IL 6IN 85S 97E AAJGR AASAJ AAYJJ ABQJQ ABVLG ACGFO ACGFS ACIWK ACKIV ACNCT ACPRK ADZIZ AENEX AETIX AFFNX AFRAH AI. AIBXA AKJIK ALLEH ALMA_UNASSIGNED_HOLDINGS ASUFR ATWAV BEFXN BFFAM BGNUA BKEBE BPEOZ CHZPO CS3 DU5 EBS EJD F5P HZ~ H~9 IAAWW IBMZZ ICLAB IDIHD IEGSK IFIPE IFJZH IPLJI JAVBF LAI MS~ O9- OCL P2P RIA RIE RIG RIL RNS TAE TN5 VH1 VJK X7M XFK ZGI ZXP 08R AAUGY ABPTK IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7U5 8FD L7M 7QO FR3 P64 |
ID | FETCH-LOGICAL-c423t-a88dd01dbd4b9f3657006dd56f24c0d1da571749bf8d23777ec9f3a6b27016cd3 |
IEDL.DBID | RIE |
ISSN | 0018-9294 |
IngestDate | Sat Aug 17 02:40:25 EDT 2024 Fri Aug 16 20:53:08 EDT 2024 Fri Aug 16 09:24:54 EDT 2024 Fri Aug 23 01:24:52 EDT 2024 Sat Sep 28 07:34:50 EDT 2024 Sun Oct 29 17:08:26 EDT 2023 Wed Jun 26 19:27:44 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Keywords | Human Delivery system Cell permeability Rodentia Electroporation Review Malignant tumor Vertebrata Mammalia Bleomycin Electric field Treatment Mouse Efficiency Animal Head and neck ENT disease Mechanism of action |
Language | English |
License | CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c423t-a88dd01dbd4b9f3657006dd56f24c0d1da571749bf8d23777ec9f3a6b27016cd3 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
PMID | 10356882 |
PQID | 21393702 |
PQPubID | 23462 |
PageCount | 8 |
ParticipantIDs | ieee_primary_764952 proquest_miscellaneous_910648544 proquest_miscellaneous_21393702 proquest_miscellaneous_28342573 pubmed_primary_10356882 crossref_primary_10_1109_10_764952 pascalfrancis_primary_1798529 |
PublicationCentury | 1900 |
PublicationDate | 1999-06-01 |
PublicationDateYYYYMMDD | 1999-06-01 |
PublicationDate_xml | – month: 06 year: 1999 text: 1999-06-01 day: 01 |
PublicationDecade | 1990 |
PublicationPlace | New York, NY |
PublicationPlace_xml | – name: New York, NY – name: United States |
PublicationTitle | IEEE transactions on biomedical engineering |
PublicationTitleAbbrev | TBME |
PublicationTitleAlternate | IEEE Trans Biomed Eng |
PublicationYear | 1999 |
Publisher | IEEE Institute of Electrical and Electronics Engineers |
Publisher_xml | – name: IEEE – name: Institute of Electrical and Electronics Engineers |
References | ref13 ref12 mir (ref23) 1991; 313 ref14 ref30 ref10 ref2 ref1 ref17 ref19 ref18 okino (ref16) 1987; 78 ref24 kanesada (ref20) 1990; 25 ref26 ref22 chang (ref11) 1992 nelson (ref28) 1994; 14 tounekti (ref27) 1993; 53 ref21 ref8 ref7 ref9 ref4 ref3 ref6 ref5 rudolf (ref25) 1995; 29 nishi (ref15) 1996; 56 nanda (ref29) 1998; 18 |
References_xml | – ident: ref5 doi: 10.1016/0005-2736(77)90252-8 – ident: ref1 doi: 10.1002/ijc.2910540413 – ident: ref2 doi: 10.3322/canjclin.46.1.5 – ident: ref19 doi: 10.1016/S0304-4165(96)00147-X – volume: 18 start-page: 999 year: 1998 ident: ref29 article-title: electroporation therapy of human larynx tumors hep-2 implanted in nude mice publication-title: Anticancer Res contributor: fullname: nanda – ident: ref8 doi: 10.1109/MEMB.1986.5006335 – ident: ref22 doi: 10.3109/10717549709052016 – ident: ref21 doi: 10.1006/bbrc.1993.1911 – ident: ref10 doi: 10.1007/978-1-4899-2528-2 – ident: ref14 doi: 10.1016/0302-4598(95)01827-2 – volume: 78 start-page: 1319 year: 1987 ident: ref16 article-title: effects of a high-voltage electrical impulse and an anticancer drug on growing tumors publication-title: Jpn J Cancer Res contributor: fullname: okino – ident: ref17 doi: 10.1016/0006-2952(88)90344-9 – ident: ref3 doi: 10.1016/0304-4165(67)90052-9 – volume: 313 start-page: 613 year: 1991 ident: ref23 article-title: electrochemotherapy, a novel antitumor treatment: first clinical trial publication-title: C R Acad Sci Paris III contributor: fullname: mir – ident: ref9 doi: 10.1016/0005-2736(85)90501-2 – ident: ref30 doi: 10.1177/000348949810700908 – volume: 14 start-page: 1815 year: 1994 ident: ref28 article-title: dna strand breaks: the dna template alterations that trigger p53-dependent dna damage response pathways publication-title: Mol Cell Biol doi: 10.1128/MCB.14.3.1815 contributor: fullname: nelson – ident: ref26 doi: 10.1016/0005-2736(94)90045-0 – ident: ref13 doi: 10.1109/MEMB.1996.936254 – ident: ref18 doi: 10.1016/0277-5379(91)90065-L – ident: ref7 doi: 10.1016/0302-4598(94)80026-X – volume: 29 start-page: 229 year: 1995 ident: ref25 article-title: electrochemotherapy with bleomycin. the first clinical experience in malignant melanoma patients publication-title: Radiol Oncol contributor: fullname: rudolf – ident: ref4 doi: 10.1007/BF01867861 – year: 1992 ident: ref11 publication-title: Guide to electroporation and electrofusion contributor: fullname: chang – volume: 53 start-page: 5462 year: 1993 ident: ref27 article-title: bleomycin, an apoptosis-mimetic drug that induces two types of cell death depending on the number of molecules internalized publication-title: Cancer Res contributor: fullname: tounekti – ident: ref12 doi: 10.1016/0305-7372(94)90013-2 – ident: ref6 doi: 10.1016/0006-291X(86)91084-3 – volume: 56 start-page: 1050 year: 1996 ident: ref15 article-title: high efficiency in vivo gene transfer using intra arterial plasmid dna injection following in vivo electroporation publication-title: Cancer Res contributor: fullname: nishi – volume: 25 start-page: 2640 year: 1990 ident: ref20 article-title: anticancer effect of high voltage pulses combined with concentration dependent anticancer drugs on lewis lung carcinoma, in vivo publication-title: J Jpn Soc Cancer Ther contributor: fullname: kanesada – ident: ref24 doi: 10.1002/(SICI)1097-0142(19960301)77:5<964::AID-CNCR24>3.0.CO;2-0 |
SSID | ssj0014846 |
Score | 2.0282836 |
Snippet | Electroporation can deliver exogenous molecules like drugs and genes into cells by pulsed electric fields through a temporary increase in cell membrane... |
SourceID | proquest crossref pubmed pascalfrancis ieee |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 752 |
SubjectTerms | Adult Aged Aged, 80 and over Animals Antimetabolites, Antineoplastic - administration & dosage Biological and medical sciences Biomembranes Biopsy Bleomycin - administration & dosage Cancer Carcinoma, Squamous Cell - drug therapy Carcinoma, Squamous Cell - pathology Cell membranes Cells Cells (biology) Chemotherapy Drug Evaluation, Preclinical Drugs Electric field effects Electroporation - instrumentation Electroporation - methods Female Head and Neck Neoplasms - drug therapy Head and Neck Neoplasms - pathology Humans In vitro Magnetic Resonance Imaging Male Mechanical permeability Medical sciences Medical treatment Mice Middle Aged Neck Neoplasms Otorhinolaryngology (head neck, general aspects and miscellaneous) Otorhinolaryngology. Stomatology Permeability Remission Induction Treatment Outcome Tumors |
Title | Electroporation therapy: a new approach for the treatment of head and neck cancer |
URI | https://ieeexplore.ieee.org/document/764952 https://www.ncbi.nlm.nih.gov/pubmed/10356882 https://search.proquest.com/docview/21393702 https://search.proquest.com/docview/28342573 https://search.proquest.com/docview/910648544 |
Volume | 46 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3fa9swEBZrH0b70HVZf7hbVjH26lSSZVne2xgJpbBBYYW-BVknvQSc0CQP7V_fk-SkTWlKn2zsE8jS6fTJd_cdIT-V09JaXuSAm3cuBci8kdzm3ElpvfEGbAyQ_acub-TVbXnb8WzHXBjnXAw-c4NwG335MLXL8KvsolII59He7mgmUqrW2mEgdcrJYRzXr6hlRyLEWR3sQmoYCEJZUSqtxcYuFMuqhKBIM8dx8amgxXbEGXee0aeU0j2PhIUh4GQyWC6agX14Qef4zo86JAcdAqW_k8p8Jh9c2yP7z3gJe-Tj387j_oVcD1OdnFmnKjQlbN3_ooYiIqcrTnKK4De8o-vIdTr1FC09UNMCitoJtUHD7o7IzWj4_89l3pVhyC1irUVutAZgHBqQTe2LECvDFECpvJCWAQdT4plQ1o3XIIqqqpxFMaMaUSGetFAck9122rrTEEel0Lg6w8AYNB5ae-eNw-1CV1Zp8Bn5sZqW8SyxbYzjKYXV4ZqGKiO9MIprgdXT_sb8PbWval2KOiPnq_kc4woKbhHTuulyPhY8kAIy8YaELoJpKzJCt0gg6FJSl1Jm5CTpyrP-J5U7e7XbX8leRwSRM_6N7C7ulq6PMGfRfI8K_giSWvnm |
link.rule.ids | 315,786,790,802,27955,27956,55107 |
linkProvider | IEEE |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Nb9QwEB2hVuLjUGChkEKphbhmsR3Hcbgh1GqBthJSK_UWOR77UilbdXcP8OsZ29ltiyjilCgZS449nnnOzDwDfNDeKOdEVSI571JJVGWvhCuFV8oFGyy6lCB7qmfn6ttFfTHybKdaGO99Sj7z03ibYvk4d6v4q-xjownOk73dJjfPm1ystQkZKJOrcrigFSxbNdIICd5Gy5CbRopQXtXaGHnHD6WDVWJapF3QyIR8pMX9mDP5nqOnuah7kSgLY8rJ5XS17Kfu1x-Ejv_5Wc9gZ8Sg7HNWmufwwA8TeHKLmXACD0_GmPsL-HGYT8q5GpWF5ZKtn5-YZYTJ2ZqVnBH8je_YJnedzQMjW4_MDkii7pK5qGPXL-H86PDsy6wcD2IoHaGtZWmNQeQCe1R9G6qYLcM1Yq2DVI6jQFvTrlC1fTAoq6ZpvCMxq3vZEKJ0WO3C1jAf_OuYSaXJvHrL0VoyH8YEH6wnh2Eapw2GAt6vp6W7ynwbXdqn8DZe81AVMImjuBFYP92_M3837ZvW1LIt4GA9nx2toRgYsYOfrxadFJEWkMt_SJgqGreqAHaPBMEurUytVAGvsq7c6n9Wub2_dvsAHs3OTo6746-n39_A45EWouTiLWwtr1d-n0DPsn-XlP033Nz9Og |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Electroporation+therapy%3A+a+new+approach+for+the+treatment+of+head+and+neck+cancer&rft.jtitle=IEEE+transactions+on+biomedical+engineering&rft.au=Hofmann%2C+G+A&rft.au=Dev%2C+S+B&rft.au=Dimmer%2C+S&rft.au=Nanda%2C+G+S&rft.date=1999-06-01&rft.issn=0018-9294&rft.volume=46&rft.issue=6&rft.spage=752&rft.epage=759&rft_id=info:doi/10.1109%2F10.764952&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0018-9294&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0018-9294&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0018-9294&client=summon |